Sponsor or institution

Clinical trials and research at Shanghai JMT-Bio Inc.

• 14Clinical trials
• 1Country

Newest trials

All recruiting trials (14)

• JMT206 injections for obesity: safety and tolerability in adults with BMI 30+

  This study tests whether different doses of JMT206 injections are safe and tolerable in adults with obesity.

  Recruiting Phase 1 Shanghai JMT-Bio Inc. · Beijing · NCT07840729

• KN026 plus HB1801 with chemotherapy as adjuvant treatment after surgery for resectable HER2-positive breast cancer

  This study will test whether giving KN026 and HB1801 with chemotherapy after surgery helps people with resectable HER2-positive breast cancer more than the usual trastuzumab plus pertuzumab with chemotherapy.

  Recruiting Phase 3 Shanghai JMT-Bio Inc. · Shanghai, Shanghai Municipality · NCT07441460

• Safety and body-response testing of JMT206 injection in healthy adults

  This will test a single dose of JMT206 injection in healthy adults to see how safe it is and how the body processes and responds to it.

  Recruiting Phase 1 Shanghai JMT-Bio Inc. · Beijing, Beijing Municipality · NCT07419698

• JMT108 injection for unresectable locally advanced or metastatic melanoma

  This trial will try an experimental medicine called JMT108 to see if it is safe and helps adults with unresectable locally advanced or metastatic melanoma, especially those who have no standard treatment options left.

  Recruiting Phase 1/2 Shanghai JMT-Bio Inc. · Beijing, Beijing Municipality · NCT07280832

• JMT106 injection for advanced solid tumors

  This first-in-human Phase 1 trial will try JMT106 injection as a single treatment for adults with advanced solid tumors who have exhausted or do not have standard therapy options.

  Recruiting Phase 1 Shanghai JMT-Bio Inc. · Zhejiang · NCT07275073

• JMT202 injections for adults with high triglycerides

  This will test whether repeated subcutaneous injections of JMT202 are safe and well tolerated in Chinese adults with high triglyceride levels.

  Recruiting Phase 1/2 Shanghai JMT-Bio Inc. · Beijing, Beijing Municipality · NCT07140809

• Investigating JMT108 Injection for Advanced Malignant Tumors

  This study is testing a new injection called JMT108 to see if it is safe and can help people with advanced tumors that haven't responded to other treatments.

  Recruiting Phase 1/2 Shanghai JMT-Bio Inc. · Shanghai, Shanghai Municipality · NCT06877650

• Evaluating JMT203 for patients with cancer cachexia

  This study is testing a new treatment called JMT203 to see if it can help people with cancer cachexia feel better and improve their health.

  Recruiting Phase 1/2 Shanghai JMT-Bio Inc. · Zhejiang · NCT06868849

• Comparing JSKN003 and T-DM1 for advanced HER2-positive breast cancer

  This study is testing whether a new treatment called JSKN003 can work better than the standard drug T-DM1 for people with advanced HER2-positive breast cancer who have already received other treatments.

  Recruiting Phase 3 Shanghai JMT-Bio Inc. · Shanghai · NCT06846437

• Evaluating glumetinib and osimertinib for lung cancer after EGFR-TKI resistance

  This study is testing if a new combination of glumetinib and osimertinib can help people with lung cancer who have stopped responding to previous treatments.

  Recruiting Phase 3 Shanghai JMT-Bio Inc. · Beijing, Beijing Municipality · NCT06829459

• Combining JMT101 with Osimertinib for advanced lung cancer treatment

  This study is testing if adding a new drug called JMT101 to the standard treatment osimertinib can help people with advanced lung cancer live better and longer.

  Recruiting Phase 3 Shanghai JMT-Bio Inc. · Guangzhou · NCT06735391

• Evaluating JMT601 for treating relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma

  This study is testing a new treatment called JMT601 to see if it can help people with relapsed or hard-to-treat CD20-positive B-cell non-Hodgkin lymphoma feel better and stay safe during the process.

  Recruiting Phase 1 Shanghai JMT-Bio Inc. · Shanghai · NCT06725524

• New treatment for HER2-positive recurrent or metastatic breast cancer

  This study is testing a new combination treatment for people with HER2-positive recurrent or metastatic breast cancer to see if it works better than the standard treatment.

  Recruiting Phase 3 Shanghai JMT-Bio Inc. · Beijing, chaoyang · NCT05838066

• KN026 combined with chemotherapy for HER2 positive gastric cancer after first-line treatment failure

  This study is testing if a new treatment called KN026 combined with chemotherapy can help people with HER2-positive advanced gastric cancer who didn't respond to their first treatment.

  Recruiting Phase 2/3 Shanghai JMT-Bio Inc. · Beijing · NCT05427383

Quick answers

How many clinical trials run by Shanghai JMT-Bio Inc. are recruiting right now?

14, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 5, Phase 1/2: 4, Phase 1: 4, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →